Validity of Parametric MRI Using VIRADS
Validity of Parametric MRI Using VIRAD Scoring in the Diagnosis of Cancer Bladder
Assiut University
58 participants
Dec 1, 2025
INTERVENTIONAL
Conditions
Summary
Our aim in this prospective study is to evaluate the validity of the non-contrast biparametric MRI (bp-MRI), including T2-WI and DWI sequences, and the availability of an alternative to the mp-MRI, for the muscle invasiveness assessment of bladder cancer using VIRAD scoring in both techniques.
Eligibility
Inclusion Criteria2
- cases of patients who suspected to have cancer urinary bladder by clinical, histopathological examination and radiological imaging.
- All age groups . Both sex
Exclusion Criteria2
- patient with high renal chemistry. Patient with contraindications to MRI as pacemaker and cochlear implants.
- \-
Interventions
All patients will be subjected to : MRI examinations on a 1.5-T MRI system in the supine position by using a 16-channel pelvic phased-array coil. The MRI proto col includes the following sequences: unenhanced axial T1-WI, high-resolution three planes (axial, coronal, and sagittal) T2-WI, axial DWI with b values of 0, 800, and 1600 s/mm2, axial DCE T1-WI with three-dimensional (3D) high temporal resolution. In all sequences, the small field of view (FOV) was used with the scope of viewing the entire bladder, proximal urethra, distal ureteral orifices, and adjacent pelvic organs. Gadopentetate dimeglumine (Gadovist, 0.1 ml/kg body weight) is administered at a rate of 2 ml/s using a power injector.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05783271